52nd week of 2017 patent applcation highlights part 24 |
Patent application number | Title | Published |
20170369559 | METHODS OF TREATING ALZHEIMER'S DISEASE - Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-Abeta antibody. Methods include the use of prognostic and/or predictive biomarkers. | 2017-12-28 |
20170369560 | HUMAN ANTI-TAU ANTIBODIES - Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively. | 2017-12-28 |
20170369561 | GLYPICAN-3-SPECIFIC ANTIBODY AND USES THEREOF - The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3. | 2017-12-28 |
20170369562 | METHODS FOR TREATING COMPLEMENT-ASSOCIATED DISORDERS - The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b. | 2017-12-28 |
20170369563 | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN - Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided. | 2017-12-28 |
20170369564 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 2017-12-28 |
20170369565 | THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS OF USING SAME - A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies comprising specific heavy chain isotypes are provided. The invention extends to the use of the immunoglobulins of the invention in methods of treating conditions such as pain, inflammatory conditions and cancerous conditions in a canine. | 2017-12-28 |
20170369566 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2017-12-28 |
20170369567 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES - The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g., purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX). | 2017-12-28 |
20170369568 | INTERFERON ALPHA ANTIBODIES AND THEIR USES - The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention. | 2017-12-28 |
20170369569 | Anti-Active GIP Antibody - Provide is an anti-active GIP antibody which allows accurate detection of active GIP. The present invention provides an anti-active GIP antibody which binds to active GIP and does not substantially bind to nonactive GIP, the antibody recognizing at least one or more amino acids selected from the group consisting of amino acids at 8 | 2017-12-28 |
20170369570 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY - The present invention includes, among other things, β-1,6-glucan linked to an antibody directed to a cell present in a tumor microenvironment. T regulatory cells can be one type of cell present in the tumor microenvironment. In particular embodiments, the antibody is directed to a surface feature of a T regulatory cell, MDSC, or other immune cell. In certain embodiments, the antibody is directed to T regulatory cells, MDSCs, or other immune cells present in a tumor microenvironment. Compositions including β-1,6-glucan linked to an antibody directed to a T regulatory cell, MDSC, or other immune cell may be useful, e.g., in the treatment of a tumor or cancer in a subject in need thereof. Accordingly, the present invention provides, among other things, methods and compositions for treatment of a tumor or cancer. | 2017-12-28 |
20170369571 | ANTI SEZ6 ANTIBODIES AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 2017-12-28 |
20170369572 | ANTI-CD47 ANTIBODIES AND USES THEREOF - Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies. | 2017-12-28 |
20170369573 | MONOMERIC FC DOMAINS - Monomeric Fc-domains are provided, as well as multimeric and single chain proteins comprising the monomeric Fc-domains. The proteins have utility in the treatment of disease. Included, inter glia, are multi specific polypeptides. | 2017-12-28 |
20170369574 | AN IMMUNOTOXIN FOR USE IN THE TREATMENT OF LEISHMANIASIS - An immunotoxin for use in the treatment of leishmaniasis A wherein the immunotoxin comprises a portion which is specifically binding to the cellular surface receptor CD64 as a component A and a cell killing portion as a component B, wherein the cell killing portion alters the function, gene expression, or viability of a cell thereby killing | 2017-12-28 |
20170369575 | SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS - Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided. | 2017-12-28 |
20170369576 | Treatment And Functional Cure Of HIV Infection By Monoclonal Antibodies To CD4 Mediating Competitive HIV Entry Inhibition - The present disclosure is directed to compositions and methods for the prevention, treatment, and/or functional cure of HIV infection. One aspect of the present disclosure relates to monoclonal antibodies directed against CD4, compositions thereof, and methods employing such compositions for the prevention, treatment, and functional cure of HIV infection. | 2017-12-28 |
20170369577 | RECOMBINANT CD74 POLYPEPTIDES - Disclosed are recombinant CD74 polypeptides mutated relative to the naturally occurring CD74 polypeptides with improved properties such as binding of CD74 ligands such as MIF and RTL1000 as well as polynucleotides that encode the polypeptides, expression vectors comprising the polynucleotides, bacteria that include the expression vectors, and methods of making the recombinant polypeptides. | 2017-12-28 |
20170369578 | REGENERATION OF AGED SATELLITE CELLS - Methods and compositions described herein are useful for rejuvenating skeletal muscle stem cells (i.e., satellite cells), promoting skeletal muscle regeneration, improving exercise endurance, regenerating skeletal muscle degeneration associated with an age-related disorder of skeletal muscle, and treating, preventing, or reversing skeletal muscle conditions. | 2017-12-28 |
20170369579 | HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1 - High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed. | 2017-12-28 |
20170369580 | ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR MONOCLONAL ANTIBODIES - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 2017-12-28 |
20170369581 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 2017-12-28 |
20170369582 | ANTI APRIL (A PROLIFERATION-INDUCING LIGAND) ANTIBODIES AND THEIR USES FOR THE PROGNOSIS AND/OR DIAGNOSIS OF CANCER - An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer. | 2017-12-28 |
20170369583 | METHODS AND COMPOSITIONS FOR TREATING LUPUS - The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms. | 2017-12-28 |
20170369584 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES - Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided. | 2017-12-28 |
20170369585 | ANTI-CD276 POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS - Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. | 2017-12-28 |
20170369586 | Humanized Anti-CD134 (OX40) Antibodies and Uses Thereof - The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment. | 2017-12-28 |
20170369587 | Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof - A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different epitopes on HER2 receptor. | 2017-12-28 |
20170369588 | PRO-APOPTOTIC ANTI-NG2/CSPG4 ANTIBODIES AND THEIR USES FOR DISEASE THERAPY - The present invention relates to an antibody capable of binding with high-affinity and high selectivity to the ectodomain of the transmembrane proteoglycan (PG) NG2/CSPG4, preferably to discrete isoforms of said PG, preferably isoforms that may be generated by alternative splicing, and/or coding single nucleotide polymorphisms, and/or post-transcriptional and/or post-translational modifications. The invention further relates to an anti-NG2/CSPG4 antibody possessing the ability to uniquely induce programmed cell death, exhibited as both canonical caspase-dependent apoptosis and authophagy, in NG2/CSPG4-expressing cancer cells. This action being manifested irrespectively of the coaction of other exogenously added factors. Moreover, the present invention refers to a composition comprising the antibody of the invention, in its naked, encapsulated or genetically engineered form, as pharmaceutical excipient. A further aspect of the present invention refers to the anti-NG2/CSPG4 molecule, or any of its isoforms and fragments, provided as proteolytically generated peptides or produced synthetically and/or recombinantly, for the treatment of apoptosis and/or autophagy-dependent diseases, including but not restricted to cancer. | 2017-12-28 |
20170369589 | BINDING MEMBERS FOR HUMAN C-MAF - The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf. | 2017-12-28 |
20170369590 | BISPECIFIC ANTIBODIES AGAINST HER2 - Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed. | 2017-12-28 |
20170369591 | PREDICTIVE MARKER FOR TOPOISOMERASE I INHIBITORS - The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase I (topo I) inhibitors in the treatment of cancers. More specifically, the present invention relates to methods, machines, computer systems, computable readable media and kits which can be used to identify and determine the effectiveness of topoisomerase I (topo I) inhibitors in the treatment of cancers, and in some embodiments, the level of sensitivity or resistance of a tumor cell to a topoisomerase I inhibitor, such as camptothecin (CPT), or CTP analogues such as topotecan and irinotecan and derivatives thereof. More specifically, the present invention related to methods, machines, computer systems, computable readable media and kits which can be used to determine the presence of phosphorylation of topoisomerase I polypeptide, in some embodiments phosphorylation at residue serine 10 (S10) of a topoisomerase I polypeptide, wherein the presence of phosphorylation, in particular the phosphorylation at serine 10 of a topoI polypeptide indicates a cancer is likely to be unresponsive to a topo I inhibitor, whereas the absence of phosphorylation, in particular, the absence of phosphorylation at residue serine 10 (S10) identifies a cancer is likely to be responsive to a topo I inhibitor. Other aspect of the present invention relate to phospho-serine10 topoisomerase I antibodies and other protein binding moieties, and uses thereof. | 2017-12-28 |
20170369592 | NOVEL ANTI-FIBROBLAST ACTIVATION PROTEIN (FAP) ANTIBODIES AND USES DERIVED THEREOF - Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics. | 2017-12-28 |
20170369593 | MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. | 2017-12-28 |
20170369594 | BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3 - Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed. | 2017-12-28 |
20170369595 | MULTISPECIFIC ANTIBODIES - The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof. | 2017-12-28 |
20170369596 | SIZE REDUCTION OF ETHYLCELLULOSE POLYMER PARTICLES - Provided is a process for reducing the size of ethylcellulose polymer particles comprising
| 2017-12-28 |
20170369597 | PHYTOGLYCOGEN NANOPARTICLES AND METHODS OF MANUFACTURE THEREOF USING CORN - An industrially scalable process for producing substantially monodisperse compositions of phytoglycogen nanoparticles from phytoglycogen-containing plant materials is provided that avoids the use of chemical, enzymatic or thermo treatments that degrade the phytoglycogen material. Also provided are phytoglycogen nanoparticle compositions produced by these processes. | 2017-12-28 |
20170369598 | METHOD FOR PRODUCING XYLAN-CONTAINING MATERIAL - An object of the present invention is to provide a method for easily extracting and efficiently recovering xylan from wood. | 2017-12-28 |
20170369599 | MODIFIED CONJUGATED DIENE POLYMER, AND POLYMER COMPOSITION CONTAINING SAID POLYMER - There is disclosed a modified conjugated diene polymer including a structural unit derived from a compound represented by formula (1), and a structural unit derived from a conjugated diene. | 2017-12-28 |
20170369600 | SUSPENSIONS IN AQUEOUS MEDIA - Provided is a suspension comprising liquid droplets dispersed in an aqueous medium, wherein said droplets comprise (a) one or more water-insoluble compounds, and (b) a vinyl polyelectrolyte (PED) having a polarity, and wherein said aqueous medium comprises a polyelectrolyte (PEW) having a polarity that is opposite to the polarity of said polyelectrolyte (PED). Also provided are a method of making such a suspension and a method using such a suspension in a process of suspension polymerization. | 2017-12-28 |
20170369601 | AQUEOUS EMULSION AND ADHESIVE IN WHICH SAME IS USED - The present invention relates to an aqueous emulsion including an ethylenically unsaturated monomer unit-containing polymer as a dispersoid and a polyvinyl alcohol as a dispersant. The content of a free polyvinyl alcohol in the aqueous emulsion is 0.2 to 20 parts by mass relative to 100 parts by mass of the ethylenically unsaturated monomer unit-containing polymer. The free polyvinyl alcohol has a degree of saponification of 80.0 to 99.5 mol % and a viscosity-average degree of polymerization of 200 to 5000, and the free polyvinyl alcohol has a symmetry factor (W | 2017-12-28 |
20170369602 | RHEOLOGY MODIFIER - A rheology modifier obtainable by polymerizing (i) at least one ethylenically unsaturated carboxylic acid; (ii) at least one nonionic ethylenically unsaturated surfactant monomer, (iii) at least one C | 2017-12-28 |
20170369603 | STYRENE-FREE COATING COMPOSITIONS FOR PACKAGING ARTICLES SUCH AS FOOD AND BEVERAGE CONTAINERS - A method of forming a coating on a food or beverage container, which includes spraying a coating composition onto an interior surface of the food or beverage container, where the coating composition includes an emulsion-polymerized latex copolymer having copolymer chains of one or more ethylenically-unsaturated monomers and one or more styrene offset monomers. Preferably, the coating composition is substantially free of BPA, PVC, and styrene. The method may also include curing the sprayed coating composition, thereby providing the coating on the interior surface of the food or beverage container. | 2017-12-28 |
20170369604 | FINELY DIVIDED, CATIONIC, AQUEOUS POLYMER DISPERSIONS, METHOD FOR THE PRODUCTION THEREOF, AND THE USE THEREOF - Finely divided, cationic, aqueous polymer dispersions, method for the production thereof, and the use thereof The present invention relates to a finely divided, cationic, aqueous polymer dispersion which is obtainable by emulsion polymerisation of ethylenically unsaturated monomers in a continuous phase containing an aqueous liquid in which the emulsion polymerisation is carried out, in the presence of polymerisation initiators, of a combination of monomers comprising (a) from 0 to less than 60% by weight of at least one optionally substituted styrene, (b) from greater than 0 to 80% of at least one C | 2017-12-28 |
20170369605 | NOVEL GROUP 4 TRANSITION METAL COMPOUND AND USE THEREOF - The present invention relates to a novel Group 4 transition metal compound, a method for preparing the compound, a catalyst composition comprising the compound, and a method for preparing a polyolefin comprising performing a polymerization reaction of olefin monomers, in the presence of the catalyst composition. Since the Group 4 transition metal compound of the present invention exhibits an excellent catalytic activity in polyolefin synthesis reactions, as well as having excellent thermal stability, it can be used for polyolefin synthesis reactions at high temperatures, and by changing the type of a central metal and ligand, the weight average molecular weight of synthesized polyolefins and the octene content in the polymer can be controlled. Therefore, it can be effectively used in polyolefin synthesis processes in which grades are controlled. | 2017-12-28 |
20170369606 | Functionalized Elastomeric Polymer Compositions, Their Preparation Methods and Crosslinked Rubber Compositions Thereof - The invention relates to an elastomeric polymer composition and its preparation. The polymer composition includes, in combination, a single terminally modified conjugated diene (co)polymer and a dual terminally modified conjugated diene (co)polymer. The polymer composition is useful in the preparation of a vulcanized and, thus, crosslinked elastomeric composition having relatively low hysteresis loss, good grip and low heat build-up properties. | 2017-12-28 |
20170369607 | ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION, METHOD FOR MANUFACTURING THREE-DIMENSIONAL OBJECTS, AND APPARATUS FOR MANUFACTURING THREE-DIMENSIONAL OBJECTS - An active energy ray liquid composition is provided. A cured product of the active energy ray curable liquid composition is a solid at 25° C. and a liquid at 60° C., and the solid exhibits a compression stress of 2.0 kPa or more when compressed 1%. | 2017-12-28 |
20170369608 | PRODUCTION METHOD FOR OLEFIN-POLYMERIZATION CATALYST AND PRODUCTION METHOD FOR OLEFIN POLYMER - A method for producing an olefin polymerization catalyst includes bringing a solid catalyst component for olefin polymerization, a vinylsilane compound, an organosilicon compound, and an organoaluminum compound into contact with each other in an inert organic solvent under an inert gas atmosphere in the absence of a specific vinyl compound, wherein a washing treatment is not performed after the vinylsilane compound has been added to the reaction system, the solid catalyst component includes a magnesium compound, a titanium halide compound, and an electron donor compound that does not include a phthalic acid ester structure, and includes a diol skeleton, and the organosilicon compound does not include a vinyl group, and includes at least one group selected from an alkoxy group and an amino group. | 2017-12-28 |
20170369609 | Ethylene-Based Interpolymers and Composition Comprising the Same - A first ethylene-based interpolymer comprising, in polymerized form, monomer units derived from ethylene and from a benzocyclobutene (VBCB) structure of Structure 1; wherein n is from 3 to 10; and wherein the ethylene-based polymer comprises, in polymerized form, from 0.02 to 0.70 wt % of the Structure 1, based on the weight of the first ethylene-based interpolymer, as determined by | 2017-12-28 |
20170369610 | ETHYLENE ACID COPOLYMERS, THEIR IONOMERS, AND THEIR USE IN PACKAGING FILMS AND INJECTION MOLDED ARTICLES - Provided are novel ethylene acid copolymers, their ionomers and their use in various articles, including packaging films and injection molded articles. The ethylene acid copolymers comprise copolymerized units of ethylene, about 10 to about 30 wt % of copolymerized units of a first α,β-unsaturated carboxylic acid having 3 to 10 carbon atoms; and about 5 to about 15 wt % of copolymerized units of a derivative of a second α,β-unsaturated carboxylic acid having 3 to 10 carbon atoms. Preferred derivatives include esters, and in particular alkyl esters. These ethylene acid copolymers and ionomers have improved optical properties when compared to conventional ethylene acrylic or methacrylic acid copolymers and their ionomers. | 2017-12-28 |
20170369611 | POWDERY DIACETAL CLARIFYING AGENT AND METHOD OF PREPARING THE SAME - Provided are a powdery diacetal clarifying agent and a method of preparing the same. The powdery diacetal clarifying agent comprises a diacetal compound and an inorganic silicon-containing compound having a pH value equal to or more than 6 and equal to or less than 12. The powdery diacetal clarifying agent of the composition can have excellent flowability, dispersability, thermal resistance, and color stability. Accordingly, the powdery diacetal clarifying agent does not release stinking odor and incur yellowing at high temperature, allowing the plastic articles to have improved appearance and visual appeal. | 2017-12-28 |
20170369612 | POLYETHYLENE FOR PIPES - The present invention provides a process for the preparation of a multimodal polyethylene comprising: (i) polymerising ethylene and optionally an α-olefin comonomer in a first polymerisation stage to produce a first ethylene polymer; and (ii) polymerising ethylene and optionally an α-olefin comonomer, in the presence of said first ethylene polymer, in a second polymerisation stage, wherein the first and second polymerisation stages are carried out in the presence of an unsupported metallocene catalyst and each polymerisation stage produces at least 5% wt of the multimodal polyethylene, and the multimodal polyethylene has a multimodal molecular weight distribution, a molecular weight of at least 50,000 g/mol and a bulk density of at least 250 g/dm | 2017-12-28 |
20170369613 | CROSSLINKABLE RESIN COMPOSITION, CROSSLINKED PRODUCT, AND METHOD FOR PRODUCING THEREOF, AND MULTILAYERED STRUCTURE | 2017-12-28 |
20170369614 | SURFACTANT RESPONSIVE EMULSION POLYMERIZED MICRO-GELS - A stable, aqueous composition containing a crosslinked, nonionic, amphiphilic polymer capable of forming a yield stress fluid in combination with a surfactant is disclosed. The yield stress fluid is capable of suspending insoluble materials in the presence of electrolytes, perfumes, fragrances and/or organic acid preservatives. | 2017-12-28 |
20170369615 | METHOD FOR THE PREPARATION OF COPOLYMERS OF ALKYL METHACRYLATES AND MALEIC ANHYDRIDE - A method for the preparation of a sulfur-free copolymer proceeds by solution polymerization in the presence of a radical initiator, wherein the copolymer contains at least one alkyl methacrylate and maleic anhydride having a number average molecular weight of 3000 to 9000 g/mol. | 2017-12-28 |
20170369616 | RESIST COMPOSITION AND PATTERNING PROCESS - A resist composition comprising a base polymer and a sulfonium or iodonium salt of iodized benzoyloxy-containing fluorinated sulfonic acid offers a high sensitivity and minimal LWR or improved CDU independent of whether it is of positive or negative tone. | 2017-12-28 |
20170369617 | METHODS OF USE FOR CROSSLINKED POLYMER COMPOSITIONS IN SUBTERRANEAN FORMATION OPERATIONS - A method comprising introducing a treatment fluid into a subterranean formation, wherein the treatment fluid comprises a base fluid and a crosslinked polymer, the crosslinked polymer comprising reactants of a first repeating unit, a second repeating unit, and a crosslinker that react to form the crosslinked polymer, wherein the first repeating unit is a sulfonic acid-containing monomer present from 50% to 99% by weight of the reactants, wherein the second repeating unit selected from the group consisting of an N-vinyl amide-containing monomer, a terminal double bond-containing monomer, and any combination thereof, and is present from 1% to 50% by weight of the reactants, and wherein the crosslinker comprises at least two olefinic bonds. | 2017-12-28 |
20170369618 | LIQUID (METH)ACRYLIC SYRUP, METHOD FOR IMPREGNATING A FIBROUS SUBSTRATE WITH SAID SYRUP, AND COMPOSITE MATERIAL PRODUCED AFTER POLYMERISATION OF SAID IMPREGNATION SYRUP - The invention relates to a viscous liquid (meth)acrylic syrup comprising:
| 2017-12-28 |
20170369619 | RADIATION-CURABLE COATING COMPOUNDS CONSISTING OF A PLURALITY OF COMPONENTS, AND THE USE OF SAME IN RELEASE-COATED SUBSTRATES - A composition contains at least one siloxane having ethylenically unsaturated, radically-polymerizable groups, and at least one hydrocarbon having 2 to 6 ethylenically-unsaturated, radically-polymerizable groups, and can be used as a release coating, said composition allowing a good degree of release behavior from adhesive compounds while at the same time also achieving a high level of adhesion of the coating to the carrier material. | 2017-12-28 |
20170369620 | ACTINIC RADIATION CURABLE POLYMERIC MIXTURES, CURED POLYMERIC MIXTURES AND RELATED PROCESSES - The present disclosure is directed to actinic radiation curable polymeric mixtures, cured polymeric mixtures, tires and tire components made from the foregoing, and related processes. | 2017-12-28 |
20170369621 | Halogenated Wax Grafted To Low Molecular Weight Polymer And Rubber Composition - A wax-polymer compound includes (a) a polymer component that is a polymerized unsaturated monomer, optionally copolymerized with a vinyl-aromatic monomer, and (b) a halogenated hydrocarbon wax component. The polymer component is grafted to the halogenated hydrocarbon wax component, and the wax-polymer compound has a number average molecular weight of about 1,000 to about 100,000, A method of making the wax-polymer compound and a coated silica particle are also disclosed. A rubber composition includes a rubber elastomer comprising a polymerized unsaturated monomer and optionally a polymerized vinyl-aromatic monomer, the elastomer having a number average molecular weight of about 100,000 to about 1,000,000. It further includes a filler in an amount of about 5 to about 200 phr, the filler comprising carbon black, silica, or both; and a wax-polymer additive. | 2017-12-28 |
20170369622 | WATER-SOLUBLE BLOCK COPOLYMER AND USE THEREOF AS A SUPPORT MATERIAL FOR 3D PRINTING - The invention relates to a novel type of sacrificial polymer or support material for 3D printing, comprising a block copolymer consisting of:
| 2017-12-28 |
20170369623 | WATER-SOLUBLE DIBLOCK COPOLYMER - The invention relates to the field of block copolymers, particularly to the field of water-soluble or water-dispersible copolymers consisting of two blocks, of which the major block is a hydrophilic thermoplastic block. More particularly, the invention relates to a block copolymer consisting of a partially or totally hydrophilic elastomeric block, with a Tg of less than 30° C. and comprising at least one hydrophilic monomer, and a water-soluble thermoplastic block with a Tg of greater than 30° C. and comprising at least one monomer bearing a carboxyl group, said copolymer being partially or totally soluble in water or in aqueous medium, and the mass proportion of the thermoplastic block being greater than 50% of the weight of said copolymer. | 2017-12-28 |
20170369624 | Aqueous Polyurethane Dispersions - The present invention relates to processes for the manufacture of aqueous polyurethane dispersions that can be used as adhesives or coatings, are solvent free and have low VOC emissions, and are environmentally friendly. Also encompassed are the dispersions as such, compositions containing them and their use as coatings and adhesives. | 2017-12-28 |
20170369625 | ADHESIVE COMPOSITION - Provided is a two component adhesive composition comprising
| 2017-12-28 |
20170369626 | ALKOXYSILANE-FUNCTIONALIZED ALLOPHANATES - The present invention relates to alkoxysilane-functionalized allophanates, to methods for production thereof, and to the use thereof. In particular, the alkoxysilane-functionalized allophanate includes the reaction product of A) at least one alkoxysilane group-containing monourethane A) of the formula 1 | 2017-12-28 |
20170369627 | ALKOXYSILANE-FUNCTIONALIZED AND ALLOPHANATE-FUNCTIONALIZED URETHANES - The present invention relates to alkoxysilane-functionalized and allophanate-functionalized urethanes, methods for the preparation thereof, coating compositions comprising these and to the use thereof. | 2017-12-28 |
20170369628 | BIODEGRADABLE POLYMER - The invention provides a class of polymeric materials being ABA tri-block or AB di-block, comprised of biodegradable segments and poly(propylene oxide) (PPO) segment and uses thereof. | 2017-12-28 |
20170369629 | EPOXY RESIN COMPOSITION - In developing epoxy resin compositions used as an adhesive for structure (structural adhesive) required to have adhesive properties, if each component is increased to further enhance the adhesive properties such as shear bond strength and peel strength, this causes problems, for example, as follows. The viscosity becomes so high that the workability deteriorates. Hence, the added amount has to be limited. Moreover, the cured product becomes excessively flexible, so that the shear bond strength deteriorates. An epoxy resin composition contains the following components (A) to (E), where the component (A) does not include the component (C): the component (A): an epoxy resin; the component (B): a blocked urethane resin; the component (C): a rubber-modified epoxy resin; the component (D): rubber particles; and the component (E): a latent curing agent. | 2017-12-28 |
20170369630 | Foams And Articles Made From Foams Containing 1-Chloro-3,3,3-Trifluoropropene (HFCO-1233zd) - The present invention relates to poured-in place polyurethane foams and polyol premixes comprising 1-chloro-3,3,3-trifluoropropene (HFCO-1233zd) and one or more additional co-blowing agents. | 2017-12-28 |
20170369631 | ALKOXYSILANE- AND ALLOPHANATE-FUNCTIONALIZED COATING MATERIALS - An alkoxysilane-functionalized and allophanate-functionalized coating material including a) a binder component of 10-99 wt % of at least one reaction product of I. and II. wherein I includes A) at least one alkoxysilane-containing monourethane A) of the formula 1 R | 2017-12-28 |
20170369632 | Ultralow Monomer Polyurethanes - The present invention relates to ultralow monomer PU prepolymers containing free NCO groups obtainable from polyols, diisocyanates and NCO-reactive compounds, obtainable by reacting at least one polyol with at least one polyisocyanate, wherein the at least one polyisocyanate is used in molar excess relative to the hydroxyl groups of the at least one polyol to obtain a polyurethane prepolymer containing free isocyanate groups; and adding at least one compound having at least one H-acidic functional group to the polyurethane prepolymer containing free isocyanate groups in an amount such that the molar ratio of the free isocyanate groups to H-acidic functional groups (NCO:XH ratio) is 2 to 15, preferably 2.5 to 10, more preferably 3 to 8. Also encompassed are methods for its production, laminating adhesives containing said prepolymer, methods of bonding substrates and the use of the described adhesives for laminating two or more films. | 2017-12-28 |
20170369633 | CURABLE AND CURED EPOXY RESIN COMPOSITIONS - Curable epoxy resin compositions are provided that are mixtures containing an epoxy resin and composite particles. The composite particles have a porous polymeric core, a nitrogen-based curing agent for an epoxy resin positioned within the porous polymeric core, and a coating layer around the porous polymeric core. The nitrogen-containing curing agent typically does not react with the epoxy resin until the curable composition is heated causing the release of the nitrogen-containing curing agent from the composite particle. Additionally, cured epoxy resins formed from the curable composition and method of forming cured epoxy resins are provided. | 2017-12-28 |
20170369634 | CURABLE FORMULATIONS FOR LAMINATING ADHESIVES - The instant invention provides a curable formulation suitable for laminating adhesive applications, and laminating adhesives made therefrom. The curable formulation suitable for laminating adhesive applications according to the present invention comprises a) a blend comprising i) an epoxy terminated polyester and at least one of ii) a maleate (poly) ester or iii) a diacrylate terminated oligomer or polymer and b) an aliphatic amine curing agent. | 2017-12-28 |
20170369635 | RAPID-SET EPOXY RESIN SYSTEMS AND PROCESS OF COATING PIPELINES USING THE EPOXY RESIN SYSTEM - Rapidly gelling epoxy resin systems include an epoxy resin, certain acrylate-functional compounds, and a curing agent mixture that includes a thiol curing agent and an amine curing agent. Gel times well less than 1 minute can be obtained. The ratio of acrylate-functional compound to thiol curing agent can be varied to adjust the gel time to precise values within a broad range. | 2017-12-28 |
20170369636 | Aromatic Amine Resin, Epoxy Resin Composition And Cured Product Thereof - There are provided an aromatic amine resin represented by the following formula (1) wherein a plurality of R | 2017-12-28 |
20170369637 | HYDROCARBONATED POLYMERS WITH TWO ALCOXYSILANE END GROUPS - The invention relates to 1) a hydrocarbonated polymer comprising two alcoxysilane end groups of formula (1), and 2) a method for producing said polymer, an adhesive composition comprising said polymer and the use of said adhesive composition. | 2017-12-28 |
20170369638 | CONTINUOUS PROCESS FOR MAKING POLYBUTYLENE TEREPHTHALATE USING PURIFIED TEREPHTHALIC ACID AND 1,4-BUTANE DIOL - Disclosed is a continuous process and device for making polybutylene terephthalate (PBT) resin, particularly high molecular weight PBT resin. Also disclosed are a device for conducting the process, and a monitoring process for determining the carboxylic acid end group concentration of the resulting PBT. | 2017-12-28 |
20170369639 | UV Absorbing Complex Polyol Polyester, Polymer Personal Care Compositions - The invention includes an UV absorbing complex polyol polyester polymer that is the product of a reaction scheme that includes: (i) the esterification of a polyol and a dianhydride, wherein the esterification is carried out under conditions that facilitate substantially only anhydride opening, to form a polyester polymer comprising at least two pendant carboxylic groups, and at least two hydroxyl groups: and (ii) the reaction of at least one pendant carboxylic group and at least one terminal hydroxyl group of the polyester polymer with an epoxide having a functional group, wherein the epoxide comprises an UV absorbing moiety.
| 2017-12-28 |
20170369640 | UV Absorbing Complex Polyol Polyester Polymer Personal Care Compositions - The invention includes an UV absorbing complex polyol polyester polymer that is the product of a reaction scheme that includes: (i) the esterification of a polyol and a dianhydride, wherein the esterification is carried out under conditions that facilitate substantially only anhydride opening, to form a polyester polymer comprising at least two pendant carboxylic groups, and at least two hydroxyl groups; and (ii) the reaction of at least one pendant carboxylic group and at least one terminal hydroxyl group of the polyester polymer with an epoxide having a functional group, wherein the epoxide comprises an UV absorbing moiety. | 2017-12-28 |
20170369641 | NOVEL METHOD FOR PREPARING HIGHLY TRANSPARENT AND HIGHLY HEAT-RESISTANT POLYCARBONATE ESTER - The present invention relates to a method for preparing a bio-based polycarbonate ester, the method comprising the steps of: (1) preparing a compound represented by chemical formula 3 by converting a compound represented by chemical formula 2 into an intermediate reactant having an easily detachable functional group, followed by a nucleophilic reaction with phenol; and (2) preparing a compound including a repeat unit represented by chemical formula 1 by a polycarbonate melt condensation polymerization of the compound represented by chemical formula 3, prepared in step (1), a compound represented by chemical formula 4, and 1,4:3,6-dianhydrohexitol. The bio-based polycarbonate ester according to the present invention can regulate merits and demerits of physical properties obtained from each repeat unit, and can be favorably used for various uses due to high degrees of transparency and heat resistance thereof. | 2017-12-28 |
20170369642 | Preparation of Highly Heat-Resistant (Co)Polycarbonates by the Transesterification Method - The present invention relates to a melt transesterification process for the production of (co)polycarbonates from diaryl carbonates and cycloalkylidene diphenols, which process comprises the addition of a monohydroxyaryl compound in an amount of 5.0 to 20.0 wt.-%, based on the total mass of the reaction mixture. The invention further relates to a (co)polycarbonate obtained by the process. | 2017-12-28 |
20170369643 | GLYCEROL-BASED POLYCARBONATES - The invention provides polymer compositions, compounds, processes, and methods of use of the polymers for drug delivery, biodegradable consumer plastics, or solvents for Li-based batteries or supercapacitors. The invention is based, at least in part, on the discovery that poly(glyceric acid carbonate)s and alkyl functionalized poly(1,2 glycerol carbonates) and poly(glyceric acid carbonate)s and pharmaceutical agent/composition functionalized poly(1,2 glycerol carbonates) and poly(glyceric acid carbonate)s represent a new type of glycerol based polymer that 1) degrade into glycerol and carbon dioxide; 2) the poly(1,2 glycerol carbonates) degrade more readily than conventional poly(1,3 glycerol carbonates; and 3) poly(1,2 glycerol carbonates) can be processed to give melts, viscous fluids, liquids, films, sheets, gels, meshes, foams, fibers, or particles. | 2017-12-28 |
20170369644 | FLAME RETARDANT RESIN COMPOSITION - A flame-retarded resin includes at least one resin for which flame retardant capability is desired and at least one triaryl silicon-containing compound (I) as flame retardant in admixture therewith and/or chemically bonded, e.g., grafted, to the resin. | 2017-12-28 |
20170369645 | BIFUNCTIONAL FLUORINATED POLYMERS COMPRISING A PLURALITY OF (PER)FLUOROPOLYETHER SEGMENTS - A polymer [polymer (P)] comprising a plurality of (per)fluoropolyether (PFPE) segments [segments (S | 2017-12-28 |
20170369646 | ESTER-LINKED SURFACE MODIFYING MACROMOLECULES - The invention relates to ester-linked surface-modifying macromolecules and admixtures thereof as shown below by the representative compounds. The admixtures can be used in industrial and medical applications where enhanced surface properties are desirable (e.g., surface properties reducing or preventing biofouling, immobilization of biomolecules, or denaturation of certain biomolecules). | 2017-12-28 |
20170369647 | PROCESSES FOR REMOVING WATER FROM A POLYETHER POLYOL - Disclosed are processes and systems for removing water from a polyether polyol that employs a controlled temperature and pressure profile. | 2017-12-28 |
20170369648 | Moisture Curable Polymer Systems Based on a Mixture of Polysilylated Polyethers - Low viscosity mixtures of polysilylated polyethers are described. The mixtures include a) 50 to 95 weight percent of one or more first polysilylated polyethers which are free of urea groups, have an average of two or more terminal hydrolysable silyl groups per molecule and have a molecular weight of 4,000 to 20,000 and 50 to 5 weight percent of one or more second polysilylated polyethers which are free of urea groups, have an average of 1.8 to 4 terminal hydrolysable silyl groups per molecule and have a molecular weight of 1000 to less than 400. The mixtures have surprisingly low viscosities, and are useful as curable components of adhesive, sealant, caulking and/or coating compositions. | 2017-12-28 |
20170369649 | POLYMER, RESIN COMPOSITION AND RESIN MOLDED PRODUCT - A polymer includes a first structural unit represented by formula (1-1), (1-2) or (1-3) and a second structural unit represented by formula (2) or (3). In the formulae (1-1) to (1-3), (2) and (3), R | 2017-12-28 |
20170369650 | POWDER COMPOSITIONS FOR LASER SINTERING - Powder compositions for laser sintering. Nylon copolymer compositions are described which provide enhanced performance in processing and finished products when used in 3D laser sintering processes. | 2017-12-28 |
20170369651 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 2017-12-28 |
20170369652 | POLYMERS OF INTRINSIC MICROPOROSITY - A polymer of intrinsic microporosity having a repeating subunit including both a spirobisindane imide moiety and an amido (lactam) moiety. | 2017-12-28 |
20170369653 | POLYAMIC ACID, POLYIMIDE, POLYIMIDE FILM AND COPPER CLAD LAMINATE USING THE SAME - A polyamic acid as a polymer of a dianhydride monomer and a diamine monomer is disclosed. The dianhydride monomer is an aromatic tetrabasic carboxylic acid dianhydride monomer. The diamine monomer comprises a diamine monomer containing pyrimidinyl and an aromatic diamine monomer. A polyimide, a polyimide film and a copper clad laminate using the polyamic acid are also provided. | 2017-12-28 |
20170369654 | CURABLE RESIN COMPOSITION - A curable resin composition comprising: (a) 27 to 60 wt % of a liquid siloxane oligomer comprising polymerized units of formula R | 2017-12-28 |
20170369655 | AMPHIPHILIC POLYMER SYSTEMS - The preparation of poly-2-oxazoline amphiphilic polymers and copolymers is described. Self-assembled particles comprising these amphiphilic polymers and which are useful for the targeted delivery of therapeutic and diagnostic agents are also described. | 2017-12-28 |
20170369656 | PLASTICIZER COMPOSITION, RESIN COMPOSITION AND METHOD FOR PREPARING THEREOF - The present invention relates to a plasticizer composition, a resin composition and a method for preparing thereof. The present invention can provide a plasticizer composition, which can improve properties required to the plasticizer composition contained in a vinyl chloride-based resin composition, such as plasticizing efficiency, volatile loss, and migration resistance, to a level equal to or better than the existing plasticizer composition, and a resin composition comprising thereof. | 2017-12-28 |
20170369657 | MASTERBATCH FOR THERMOPLASTIC POLYURETHANE YARN AND METHOD FOR MANUFACTURING THERMOPLASTIC POLYURETHANE YARN USING THE SAME - The present invention relates to masterbatches for a TPU yarn and a method for manufacturing a TPU yarn using the same wherein while TPU is not coated onto the surface of a polyester or nylon yarn, unlike the above-mentioned prior arts, the masterbatches are made by compounding the TPU and nano silica, and next, they are compounded with TPU, so that the compounded material is melted and extruded through an extruder for yarn processing, thereby manufacturing a TPU yarn having no core. | 2017-12-28 |
20170369658 | METHOD FOR FABRICATION OF HIGH DISPERSION POLYMER NANOCOMPOSITES - The present invention includes the efficient dispersion and high loading of fillers in a thermoplastic polymer matrix. In a first general embodiment, the present invention includes a method wherein fillers are first synthesized and dispersed in a liquid monomer. The liquid monomer is then polymerized to a solid. The nanofillers may be silver nanoparticle/nanowire fillers. Ethylene glycol may serve as a solvent, reducing agent as well as precursor monomer for polymerization. In a second general embodiment, the present invention includes a method wherein fillers may be separately synthesized (or obtained commercially) and then added and dispersed in a liquid monomer. The liquid monomer is then polymerized to a solid. In a third general embodiment, a composite is synthesized using interfacial polycondensation. This is accomplished by aggressive mixing of two solvents during the reaction. The aggressive mixing forms microdroplets (i.e., emulsion) and hence dramatically increases the interface area thereby to a much faster polymerization rate. | 2017-12-28 |